Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 7, 2006; 12(45): 7391-7391
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7391
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7391
Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab
Jason Seewoodhary, Senior House Officer in Haematology and Bone Marrow Transplantation, University Hospital of Wales, Heath park, Cardiff, CF14 4XW, United Kingdom
Correspondence to: Dr. Jason Seewoodhary, B.Sc (Hons), MBBCh (Hons), Senior House Officer in Haematology and Bone Marrow Transplantation, University Hospital of Wales, Heath park, Cardiff, CF14 4XW, United Kingdom. seewoodharyj@hotmail.com
Telephone: +44-2920-747747 Fax: +44-2920-742167
Received: October 10, 2006
Revised: October 28, 2006
Accepted: November 7, 2006
Published online: December 7, 2006
Revised: October 28, 2006
Accepted: November 7, 2006
Published online: December 7, 2006
Abstract
Rituximab has been associated with the development of cytomegalovirus enterocolitis in immunosuppressed patients. A 51-year-old patient with diffuse large B-cell lymphoma who received a conditioning chemotherapy regimen (RCVP and RICE) consisting of rituximab before bone marrow transplantation went on to develop cytomegalovirus enterocolitis. This supports evidence from previously described cases that rituximab may be associated with cytomegalovirus enterocolitis.
Keywords: Rituximab; Cytomegalovirus; Enterocolitis; Diffuse large B-cell lymphoma; Immunosuppression